

The Job is Not Yet Over

F MAHBOOB

Department of Medicine, King Edward Medical College, Lahore
Correspondence to Dr. Fatima Mahboob, Assistant Professor

Cirrhosis of liver is a chronic disease. Chronic dysfunction of liver disturbs different body functions and metabolic pathways. As cases of chronic liver disease are on the increase⁶, a multidisciplinary approach is needed for the welfare of the patients. Usually the discharge slips of the admitted patients are prepared by adjustment of dosage in different circumstances. The aim of the present study is to highlight the importance of the knowledge of the patient about their disease and its expected complications. It is prospective hospital based case study. One hundred patients of cirrhosis of liver were included in the study. The patients were admitted in North Medical Ward of Mayo Hospital, Lahore during February 2002 to February 2003. A questionnaire was prepared and the required information was obtained from the patient/attendant and was recorded in the proforma. The patients are not having much information about the amount of salt to be taken. No clear idea about water intake, protein intake and daily caloric intake. They are not aware of modifying or adjusting the dosage of different drugs. Many complications are avoidable. It is a chronic process. The patient's education is a must to improve quality of life, to decrease number of hospital admissions and to lessen the misery of rest of the family due to repeated admissions.

Key word: Liver cirrhosis, education, management

Liver cirrhosis is associated with a spectrum of characteristics clinical manifestation. Loss of functioning hepatocellular mass eventually leads to liver insufficiency. It may cause jaundice, oedema, coagulopathy and a variety of metabolic abnormalities. Complications of liver cirrhosis may not be directly life threatening but cause impairment of quality of life e.g., jaundice causes abnormal appearance and social eviction, pruritis causes behavioural disturbance, sleep deprivation, skin lesions and skin infection. Similarly ascites causes body deformation and impaired mortality, impaired digestion, decreased lung capacity, fullness after meals, early satiety, oesophageal reflux, pain and discomfort due to intestinal wall stretching. Certain complications may be directly life threatening like portal hypertension causes variceal or ulcer bleeding, portosystemic shunts causing metabolic skip and encephalopathy. Hepatopulmonary shunts cause pulmonary hypertension, hypoxia and sudden death.

Liver insufficiency causes hypoglycemia, hyperglycemia, acid-base disturbance, electrolyte imbalance, due to wide spectrum of manifestations and complications different patients present differently. In some patients resistant ascites may be the dominant complaint while the others may give recurrent history of hematemesis and melena. As the disease progresses it requires long term medical supervision and careful management. The role of the physician is to anticipate these complications and try to avoid these. Pick the early cases and do the needful. Early management avoids a lot of discomfort and expenditure. It should be realized that conventional treatment is supportive as cure is not possible. Done is done – what you can do is to avoid further harm to the bad liver.

Patients and methods

This is a prospective, hospital based study. One hundred consecutive patients of chronic liver disease admitted in North Medical Ward, Mayo Hospital, Lahore during the period from February 2002 to February 2003 were included in the study. All the subjects were asked to complete a questionnaire. In case of unconscious patients the required information was taken from their attendants or from the patient after recovery from coma. The following points were noted down.

Name, age, sex, duration of disease, cause of chronic liver dysfunction, purpose of admission, number of previous hospital admissions, purpose of admission each time, number of outdoor visits in the past, purpose of each visit, qualification of the patients, knowledge of the patient about salt and water intake, number of stools per day, what to do if the number is more or less than required, advice about i.v. fluids, and herbal medicines, advice about immunization and prophylaxis of infection, immunization status and precautionary measures of the rest of the family. Diet instructions and adjustment of drug dosage due to changes in weather or other coexisting disease like gastroenteritis, fever or septicaemia.

The data was analysed in detail.

Results and observations:

Out of one hundred patients 55 were male and 45 female. The age distribution was shown in Table 1.

Table 1. Age distribution

Age in years	Male	Female
15-20	3	-
21-30	15	2
31-40	12	28
41-50	25	12
51 or more	-	3

Table 2. Time period after diagnosis of liver disease.

Years	n=
½ -1	20
1-3	53
3-6	22
More than 6 years	5

Table 3 Number of hospital admission after diagnosis

No. of admission	n=
1-2 times	16
2-4 times	48
4-6 times	28
More than 6 times	8

Table 4. Number of hospital outdoor visits since their diagnosis.

No. of OPD visits	n=
1-5 times	30
5-10 times	62
10-15 times	5
More than 15 times	3

Table 5. Purpose of hospital admission

Purpose of visit	n=
a) Hepatic encephalopathy	48
*Due to constipation	28
*GIT bleed	16
*Fever	4
b) Bleeding varices without encephalopathy	42
c) Resistant ascites	10

Table 6. Purpose of visit in outpatient department

	n=
Resistant ascites	73
Fever	10
Increasing weakness and lethargy	7
Muscle cramps	3
Increasing jaundice	2
Epigastric tenderness	1
Vomiting	2
Diarrhoea	2

Table 7. Immunization status

Immunization status	n=
Immunization of patients against other hepatitis viruses	Nil
Immunization against other disease like typhoid, influenza etc.	Nil
Immunization of attendants against hepatitis A virus	Nil
Immunization of attendants against hepatitis B virus	5 families

Table 8. Knowledge of patients

	n=
Amount of water intake/day	63
No. of stools/day	72
Amount of salt intake/day	23
Amount of protein intake/day	26
Adjustment of dosage	7
Caloric intake/day	13
Weight record	2

Table 9. Help of other modalities

	n=
Visit to quacks	80
Use of herbal medicine	47
Visits to clergymen	9
Self medication	7

Table 10. Qualification of patients

Education status	n=
Nil	13
Primary school	17
Middle school	37
High school	29
College education	03
Postgraduation	01

Discussion

Normal liver is performing many functions so impairment of its function causes many problems. The physician should identify each problem and deal accordingly²⁴. Malnutrition of the patient is a major problem. Cause of malnutrition may be a delay in the diagnosis or delay in planning diet chart for each patient. Poor palatability of the diet due to salt restriction, undue protein restriction, anorexia or nausea, fasting due to repeated procedures and investigations, increased endogenous protein catabolism all lead to malnutrition. Once malnutrition sets in it becomes increasingly difficult to treat it. Malnutrition leads to proximal muscle wasting, hypoalbuminemia causes worsening of ascites and decreased resistant to infections. Weak end connective tissue may predispose to variceal haemorrhage, umbilical hernia and poor wound healing.

The patient should consume dense caloric^{1,17} formula e.g., 0.8 to 1 Kcal/ml. Whey formula better than casein enriched in branched chain amino acids 30% should be fat with 15% as middle chain triglycerides. Complex polysacchrides should constitute about 60% of energy intake. The amount of proteins that can be tolerated by people with cirrhosis varies considerably. Usually there is a small margin of safety in such patients. Usually 60g of proteins per day are adequate and it should be decreased in cases of hepatic encephalopathy. Long term protein restriction is no more advocated as it causes resistant ascites. There is no limit on vegetable proteins as in creased uptake of branched chain aminoacids is very beneficial^{13,14,15,16,21,22,23,29}. In severe liver failure there is a very high level of aromatic aminoacids like phenylalanine, methionine and tyrosine that may suggest diets low in these amino acids should be used. The patient should use a diet rich in fresh fruits and vegetables. Antioxidant vitamins, calcium and other minerals should be supplemented to meet the specific requirement^{16,26}.

Zinc supplementation^{18,25} may reduce frequency and severity of muscle cramps. It improves taste sensation in these patients. Zinc is a cofactor in various enzymatic processes and its deficiency impairs aminoacid metabolism. So zinc replacement may even protect against hepatic encephalopathy^{27,28,29}. Restricting salt intake to less than 2000mg a day is advised for the patients with ascites. The less the salt the better it is.

It should be strongly noted that natural or herbal medicines are not quality controlled. There have been a number of serious and even lethal side effects. Certain studies favour the use of silybum marianum⁴ for the therapy of liver disease. However, the patient is advised not to use any such medicines without the knowledge of their physician.

The patient should be explained about factors¹¹ causing encephalopathy, so that they can avoid such factors like constipation or heavy protein diet. They should be advised for early consultation in case of infection or GI bleed. Hepatic encephalopathy must be distinguished from other neurological problems that are common in cirrhosis including organic brain syndrome with dementia, epilepsy and subdural haematoma. Lactulose dose should be adjusted to produce 2-4 stools per day. The patient is advised for self adjustment of the dosage in case the required number is not produced.

Ascites is also a major problem^{2,3,5,10}. Its presence indicates a poor prognosis. It predisposes to complications like SBP¹⁹ and hepatorenal syndrome. Resistant ascites is defined as ascites unresponsive to 400mg of spironolactone, 30mg of amiloride plus 160mg of Furosemide daily for two weeks.

The patients who cannot tolerate diuretics because of side effects are also regarded as cases of resistant ascites. Spironolactone is given in an initial dosage of 3mg/kg/day adapted to reach the naturetic effect. Urinary sodium should be high than potassium excretion. Unnecessary fluid restriction causes discomfort and indirectly insufficient caloric intake. The patients should maintain their weight record chart and they should modify the dose in case of fever or gastroenteritis.

Varices may occur at many places but those in the oesophagus and stomach are particularly likely to rupture and bleed. The patients should be advised to take drugs regularly to lower the portal pressure.

Immunisation is often neglected. Immunisation against other hepatitis viruses, pneumococcal and influenza virus is recommended. Of these the most important is probably hepatitis A vaccine. Bacterial infections are of particular concern as these are poorly tolerated. The factors responsible for that are malnutrition with impaired cell mediated immunity, decreased integrity of the bowel wall leading to bowel translocation and impaired activity of the hepatic and splenic reticuloendothelial system. Usually the infections are hospital acquired. The most common bacterial infections are urinary tract infection, pneumonia and SBP. Septicaemia causes hypotension, progressive pre-renal azotemia with hepatorenal syndrome and hepatic encephalopathy. Risk of infections should be reduced by antibiotic prophylaxis^{8,9}.

Certain medicines worsen the liver function. Sedatives and narcotics are best avoided. Drugs that are eliminated by the liver should be used in a low dosage especially the drugs which have high first pass hepatic clearance. Potentially hepatotoxic drugs present a difficult problem because hepatotoxicity may be difficult to diagnose more over consequences of hepatotoxicity superimposed on already bad liver may be devastating. Non steroidal anti-inflammatory drugs aggravate renal self retention so these should be avoided.

From the above discussion we understand that just writing the medication to the patient is not enough. The physician should have a sound knowledge of the pathophysiology of the progressive disease process and he should share the knowledge with the patient and his attendants. This in the long run will reduce the number of hospital admissions and decrease the morbidity and mortality rate.

References

1. Leiber CS. Nutrition in liver disorders. In: Shils ME, Olson JA, Snike M, Ross AC (eds) *Modern Nutrition in Health and Disease* 9th ed. Baltimore, MD: Williams and Wilkins, 1999: 1179-80.
2. Ranyon BA. Management of adult patients with ascites caused by cirrhosis. *Hepatology* 1998; 27(1): 264-72.
3. Ryunyou BA. Refractory ascites. *Semin Liver Dis* 1993; 13(4): 343.
4. Flora K, Hahn M, et al. Milk thistle (Silybum marianum) for the therapy of liver disease. *Am J Gastroenterol* 1998; 93(2): 139-43.
5. Quintero E, Gines P et al. Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. *Lancet* 1985; 1(8429): 611-2.
6. Mahfooz ur Fehman, Gul Naz Akhtar, Yasmin Lodhi. Seroprevalence of hepatitis C antibodies in blood donors. *Pak J Med Sci* 2000, 18(3): 193-96.
7. Vanto S, Garofano T, Renzini C et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. *N. Eng J Med* 1998; 338(5): 286-90.

8. Bernard B, Gronge JD, Khac EN et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with ascites: a meta analysis, *Digestion* 1998; 59(Suppl 2): 54-7.
9. Bernard B, Grange JD, Khac EN et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a metaanalysis. *Hepatology* 1999p; 29(6): 1655-6.
10. Gines P, Arroyo V, Rodes J. pathophysiology complications and treatment of ascites. *Clin Liver Dis* 1997; 1: 129-55.
11. Mullen KD, Dasarathy S. Hepatic encephalopathy. In: Schiff ER, Sorrell MF, Maddrey SC, eds. *Schiff's diseases of the liver*. Philadelphia: Lippincott-Raven 1999; 545-8.
12. Howefs JC, Runyon BA. Spontaneous bacterial peritonitis. *Dis Mon* 1985; 31(9): 1-48.
13. Egberts EH, Schomerus H, Hamster W, Jurgens P. Branched chain amino acids in the treatment of latent portosystemic encephalopathy. *Gastroenterol* 1985; 88: 887-95.
14. Dioguardi FS, Brigatti M, DellOca M et al. Effects of chronic oral branched-chain aminoacid supplementation in a subpopulation of cirrhotics. *Clin Physiol Biochem* 1990; 8: 101-7.
15. Marchesini G, Dioguardi FS, Bianchi GP et al. Long term oral branched-chain aminoacid treatment in chronic hepatic encephalopathy. A randomized double blind case in controlled trial. The Italian Multicentre Study Group. *J Hepatol* 1990; 11: 92-101.
16. Kato M, Miwa Y, Tajika M et al. Preferential use of branched - chain amino ascites as an energy substrate in patients with liver cirrhosis. *Internal Med* 1998; 37: 429-34.
17. Lochs H, Plauth M. Liver cirrhosis: rationale and modalities for nutritional support. The European Society of parenteral and enteral nutrition consensus and beyond. *Curr Opin Clin Nutr Metab Care* 1999; 2: 345-9.
18. Weismann K, Christensen E, Dreyer V. Zinc supplementation in alcoholic cirrhosis. A double-blind clinical trial. *Acta Med Scand* 1979; 205(5): 361-6.
19. Nompleggi DJ, Bonkovsky HL. Nutritional supplementation in chronic liver disease: an analytical review. *Hepatology* 1994; 19: 518-33.
20. Horst D, Grace ND, Conn HO et al. Comparison of dietary protein with an oral, branched chain-enriched aminoacide supplement in chronic portalsystemic encephalopathy: a randomized controlled trial. *Hepatology* 1984; 4: 279-87.
21. Okita M, Watanbe A, Nagashima H. Treatment of liver cirrhosis with branched chain aminoacid supplemented diet. *Gastroenterol Jpn* 1981; 16: 389-92.
22. Maddrey WC. Branched chain amino acid therapy in liver disease. *J Am Coll Nutr* 1985; 4: 639-50.
23. Wahren J, Denis J, Desurmont P et al. Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study, *Hepatology* 1983; 3(4): 475-80.
24. Hoofnagle JH, DiBisceglie AM. The treatment of chronic viral hepatitis. *N Engl J Med* 1997; 336: 347-356.
25. Taniguchi S, Kancto K, Hamada T. Acquired zinc deficiency associated with alcoholic liver cirrhosis. *Int J Dermatol* 1995; 34: 651-2.
26. Scholmerich J, Lohle E, Kottgen E, Gerok W. Zinc and vitamin A deficiency in liver cirrhosis. *Hepatogastroenterology* 1983; 30: 1195.
27. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Reslts of a randomized controlled trial. *Lancet* 1984; 2(8401): 493-5.
28. Marchesini G, Fabbri A, Bianchi G et al. Zinc supplementation and amino acid nitrogen metabolism in patients with advanced cirrhosis. *Hepatology* 1996; 23: 1084-92.
29. Sturmiolo GC, D'Inca R, Parisi G et al. Taste alterations in liver cirrhosis: are they related to zinc deficiency? *J Trace lem Electrolytes Health Dis* 1992; 6: 15-9.